Penn and CHOP researchers want to develop urea cycle disorder treatments using CRISPR gene-editing therapy. Get unlimited access to Inquirer.com and The Inquirer App, plus 5 articles each month to ...
The “plausible mechanism pathway” will allow personalised drugs to reach the market sooner for patients with genetic diseases.
In this interview, Dr. Kelemen discusses the advantages of lipid-based delivery systems and their potential to expand the reach of CAR T-cell therapies into solid tumor indications.
FDA Commissioner Marty Makary and Vinay Prasad, director of the Center for Biologics Evaluation and Research (CBER), describe ...
US regulators laid out new guidelines for approving custom-made treatments for individual patients, a move that could bring ...
Operator: Good morning, everyone. And welcome to the Abeona Therapeutics third quarter 2025 conference call. At this time, ...
While most BioSpace LinkedIn poll respondents believe the job market won’t improve until at least 2027, two industry experts ...
FDA Commissioner Marty Makary announced FDA’s plans for a new drug approval pathway named the Plausible Mechanism Pathway which will provide individual drug makers the ability to receive FDA approval ...
Unlock the four zones of AI readiness and discover why sandboxing is the smartest strategy for executive-led transformation.
Unpredictable communication and a lack of transparency are eroding the industry’s and the public’s trust. The FDA, experts ...
A naturally occurring protein, FGD3, has been shown to boost the effectiveness of chemotherapies and immunotherapies by rupturing cancer cells disrupted by these drugs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback